Intech Investment Management LLC lowered its position in Johnson & Johnson (NYSE:JNJ – Free Report) by 24.7% during the third quarter, HoldingsChannel.com reports. The fund owned 220,159 shares of the company’s stock after selling 72,363 shares during the quarter. Johnson & Johnson accounts for approximately 0.6% of Intech Investment Management LLC’s holdings, making the stock its 22nd largest holding. Intech Investment Management LLC’s holdings in Johnson & Johnson were worth $58,285,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
A number of other institutional investors and hedge funds have also modified their holdings of the company. Bridgewealth Advisory Group LLC increased its stake in Johnson & Johnson by 7.5% in the 3rd quarter. Bridgewealth Advisory Group LLC now owns 2,638 shares of the company’s stock valued at $698,000 after purchasing an additional 185 shares in the last quarter. Alaska Wealth Advisors LLC purchased a new stake in Johnson & Johnson during the third quarter worth $378,000. Morse Asset Management Inc boosted its position in Johnson & Johnson by 2.5% during the third quarter. Morse Asset Management Inc now owns 26,894 shares of the company’s stock worth $7,120,000 after purchasing an additional 663 shares in the last quarter. GatePass Capital LLC boosted its position in Johnson & Johnson by 80.2% during the third quarter. GatePass Capital LLC now owns 1,923 shares of the company’s stock worth $509,000 after purchasing an additional 856 shares in the last quarter. Finally, Silver Oak Securities Incorporated grew its holdings in Johnson & Johnson by 10.8% in the third quarter. Silver Oak Securities Incorporated now owns 11,992 shares of the company’s stock valued at $3,312,000 after purchasing an additional 1,170 shares during the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.
Insider Transactions at Johnson & Johnson
In related news, EVP Timothy Schmid sold 33,597 shares of the company’s stock in a transaction that occurred on Wednesday, September 2nd. The shares were sold at an average price of $274.74, for a total transaction of $9,230,439.78. Following the transaction, the executive vice president owned 25,447 shares of the company’s stock, valued at approximately $6,991,308.78. This represents a 56.90% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, EVP Elizabeth Forminard sold 13,072 shares of the firm’s stock in a transaction that occurred on Thursday, November 12th. The stock was sold at an average price of $284.39, for a total transaction of $3,717,546.08. Following the sale, the executive vice president owned 16,994 shares in the company, valued at approximately $4,832,923.66. This trade represents a 43.48% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 0.16% of the company’s stock.
Wall Street Analysts Forecast Growth
A number of research analysts have recently weighed in on JNJ shares. Johnson Rice cut Johnson & Johnson from a “buy” rating to a “hold” rating in a research report on Wednesday, October 21st. HSBC lifted their price target on Johnson & Johnson from $290.00 to $320.00 and gave the stock a “buy” rating in a research note on Thursday, September 10th. Morgan Stanley decreased their price objective on shares of Johnson & Johnson from $294.00 to $292.00 and set an “overweight” rating on the stock in a research report on Thursday, October 15th. Royal Bank Of Canada lowered their price objective on shares of Johnson & Johnson from $290.00 to $280.00 and set an “outperform” rating on the stock in a research note on Wednesday, October 14th. Finally, Bank of America restated a “neutral” rating and set a $278.00 target price on shares of Johnson & Johnson in a report on Tuesday, September 29th. One research analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and eight have issued a Hold rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $275.92.
Read Our Latest Analysis on JNJ
Trending Headlines about Johnson & Johnson
Investors following JNJ have been watching these headlines:
- Positive Sentiment: A Johnson & Johnson prostate-cancer drug combination is advancing into Phase 3, a meaningful clinical milestone that could strengthen the company’s oncology pipeline, although trial and commercial outcomes remain uncertain. Johnson & Johnson stock advances as prostate drug combo enters Phase 3
- Positive Sentiment: JNJ has risen 10.4% since its latest earnings report, and State Street’s Health Care SPDR added shares on Nov. 10. These reports suggest continued investor interest, though neither guarantees further gains. Johnson & Johnson Up 10.4% Since Last Earnings Report State Street Health Care SPDR Adds Johnson & Johnson
- Neutral Sentiment: J&J also led a $100 million funding round for Delix Therapeutics’ depression-drug development. This broadens its exposure to emerging psychiatric treatments, but clinical-stage programs carry substantial execution risk. Johnson & Johnson Backs New Cancer Device And Leads $100 Million Depression Bet
Johnson & Johnson Stock Up 0.0%
JNJ opened at $285.78 on Monday. The firm has a market cap of $687.95 billion, a P/E ratio of 43.30, a PEG ratio of 2.82 and a beta of 0.22. The business’s fifty day simple moving average is $266.97 and its 200 day simple moving average is $249.85. Johnson & Johnson has a 52 week low of $193.55 and a 52 week high of $288.11. The company has a quick ratio of 0.74, a current ratio of 1.02 and a debt-to-equity ratio of 0.44.
Johnson & Johnson (NYSE:JNJ – Get Free Report) last announced its earnings results on Tuesday, October 13th. The company reported $2.59 earnings per share for the quarter, beating the consensus estimate of $2.53 by $0.06. Johnson & Johnson had a net margin of 16.20% and a return on equity of 31.64%. The firm had revenue of $25.40 billion during the quarter, compared to the consensus estimate of $25.38 billion. During the same quarter in the previous year, the company posted $2.80 EPS. The firm’s revenue for the quarter was up 5.9% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. As a group, equities research analysts anticipate that Johnson & Johnson will post 11.12 EPS for the current fiscal year.
Johnson & Johnson Dividend Announcement
The company also recently declared a quarterly dividend, which will be paid on Tuesday, December 8th. Stockholders of record on Tuesday, November 24th will be issued a dividend of $1.34 per share. The ex-dividend date is Tuesday, November 24th. This represents a $5.36 dividend on an annualized basis and a dividend yield of 1.9%. Johnson & Johnson’s payout ratio is 81.21%.
Johnson & Johnson Profile
Johnson & Johnson is a global healthcare company that develops and sells prescription medicines and medical technologies. Its business is organized around two segments: Innovative Medicine and MedTech. Innovative Medicine develops treatments in areas including oncology, immunology, neuroscience, cardiovascular and metabolic disease, and pulmonary hypertension. MedTech provides products and technologies for fields such as surgery, orthopedics, and vision care. Founded in 1886, Johnson & Johnson serves patients and healthcare professionals in markets around the world.
Recommended Stories
- Five stocks we like better than Johnson & Johnson
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ – Free Report).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.
